U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H29N5O3
Molecular Weight 435.5188
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALSARTAN, D-

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@H](C(C)C)C(O)=O

InChI

InChIKey=ACWBQPMHZXGDFX-JOCHJYFZSA-N
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1

HIDE SMILES / InChI
Molecular Formula C24H29N5O3
Molecular Weight 435.5188
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009869

Valsartan (DIOVAN®) is a tetrazole derivative, and specific angiotensin II type 1 (AT1) receptor blocker that is indicated for the treatment of hypertension, to lower blood pressure. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme. Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan (DIOVAN®) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.

CNS Activity

CNS Active
3913
Curator's Comment: LBQ657 (an LCZ696 metabolite) achieves CSF concentrations sufficient to inhibit neprilysin, but LCZ696 did not cause changes in CSF levels of aggregable Abeta isoforms (1-42 and 1-40) compared with placebo

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 2.38 nM [Ki]
Inhibitor
8297
 2.3 nM [IC50]
Blocker
537
 2.43 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ENTRESTO

Approved Use

ENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

Launch Date

2015
Primary
Approved
8429
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

2011
Primary
Approved
8429
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

2011
Palliative
Approved
8429
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2808 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5756 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.141 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20650 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34310 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.56 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.45 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.55 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.24 mg single, oral
Overdose
Dose: 2.24 mg
Route: oral
Route: single
Dose: 2.24 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
Other AEs: Muscle cramps...
Other AEs:
Muscle cramps (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Disc. AE: Hyperkalemia...
Other AEs: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (1 patient)
Other AEs:
Dizziness (8.3%)
Headache (9.2%)
Back pain (5.8%)
Upper respiratory tract infection (5.8%)
Nasopharyngitis (5%)
Diarrhea (5%)
Hypoglycemia (5%)
Peripheral edema (4.2%)
Nausea (4.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
pregnant
Health Status: pregnant
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (2.3%)
Dizziness (2.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Disc. AE: Creatinine increased, Potassium increased...
AEs leading to
discontinuation/dose reduction:
Creatinine increased (0.5%)
Potassium increased (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Muscle cramps 1 patient
2.24 mg single, oral
Overdose
Dose: 2.24 mg
Route: oral
Route: single
Dose: 2.24 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
Hyperkalemia 1 patient
Disc. AE
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Nausea 4.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Peripheral edema 4.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Diarrhea 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Hypoglycemia 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Nasopharyngitis 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Back pain 5.8%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Upper respiratory tract infection 5.8%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Dizziness 8.3%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Headache 9.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Disorder fetal Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
pregnant
Health Status: pregnant
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
Dizziness 2.3%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Headache 2.3%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Creatinine increased 0.5%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Potassium increased 0.5%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9927
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9927
ChemicalBook
CB14657818
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB14657818
ChemicalBook
CB23133442
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23133442
ChemicalBook
CB34813436
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB34813436
ChemicalBook
CB3952405
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3952405
ChemicalBook
CB6182539
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6182539
MolPort
MolPort-002-507-854
https://www.molport.com/shop/molecule-link/MolPort-002-507-854
MolPort
MolPort-003-666-608
https://www.molport.com/shop/molecule-link/MolPort-003-666-608
Selleck Chemicals
Valsartan(Diovan)
http://www.selleckchem.com/products/Valsartan(Diovan).html
ZINC
ZINC000003875259
http://zinc15.docking.org/substances/ZINC000003875259
eMolecules
1989469
https://www.emolecules.com/cgi-bin/more?vid=1989469
eMolecules
2724803
https://www.emolecules.com/cgi-bin/more?vid=2724803
eMolecules
32278148
https://www.emolecules.com/cgi-bin/more?vid=32278148
eMolecules
33507560
https://www.emolecules.com/cgi-bin/more?vid=33507560
PubMed

PubMed

TitleDatePubMed
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
1993 Oct
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
1994
Binding of valsartan to mammalian angiotensin AT1 receptors.
1995 Nov 10
Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist.
1996 Jun-Jul
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester.
1996 Nov 8
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
1996 Sep
Enantiomeric LC separation of valsartan on amylose based stationary phase.
2009 Aug
Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
2014 Apr
Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis.
2015
LCZ696 : a new paradigm for the treatment of heart failure?
2015 Feb
Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
2016
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
2016 Apr
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
2016 Aug
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
2016 Jan
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
2016 Mar
Patents

Patents

US20050010053
4
US5399578
4
US5965592
4
US6294197
4
US8475839
4
WO/2016/151525A1
4
null
6

Sample Use Guides

In Vivo Use Guide
The recommended starting dose of ENTRESTO, previously known as LCZ696, is 49/51 mg (sacubitril/valsartan) twice-daily. Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
Route of Administration: Oral
In Vitro Use Guide
Sources: Von Lueder TG, Wang B, Kompa A, Huang L, Webb R, Jordan P, Krum H. ARNi, combined neprilysin and angiotensin receptor inhibition augments anti-fibrotic and anti-hypertrophic effects in vitro. Eur.Heart J. 2012;33:P5834.
Curator's Comment: ...
30 nM to 1 uM valsartan (LCZ696 component) in the presence of 10 uM LBQ657 (Sacubitril (LCZ696 component) metabolite) demonstrate anti-fibrotic and anti-hypertrophic effects on rat cardiac fibroblasts and cardiomyocytes, respectively, cultured with 100 nM angiotensin II
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:58:51 GMT 2023
Edited
by admin
on Sat Dec 16 09:58:51 GMT 2023
Record UNII
IDC67444MI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALSARTAN, D-
Common Name English
VALSARTAN RELATED COMPOUND A [USP-RS]
Common Name English
VALSARTAN IMPURITY A [EP IMPURITY]
Common Name English
VALSARTAN RELATED COMPOUND A [USP IMPURITY]
Common Name English
VALSARTAN RELATED COMPOUND A
USP   USP-RS  
Common Name English
D-VALSARTAN
Common Name English
D-VALINE, N-(1-OXOPENTYL)-N-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
CGP-49309
Code English
(2R)-3-METHYL-2-(PENTANOYL((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)AMINO)BUTANOIC ACID
Systematic Name English
Code System Code Type Description
PUBCHEM
5284633
Created by admin on Sat Dec 16 09:58:51 GMT 2023 , Edited by admin on Sat Dec 16 09:58:51 GMT 2023
PRIMARY
FDA UNII
IDC67444MI
Created by admin on Sat Dec 16 09:58:51 GMT 2023 , Edited by admin on Sat Dec 16 09:58:51 GMT 2023
PRIMARY
CAS
137862-87-4
Created by admin on Sat Dec 16 09:58:51 GMT 2023 , Edited by admin on Sat Dec 16 09:58:51 GMT 2023
PRIMARY
RS_ITEM_NUM
1708773
Created by admin on Sat Dec 16 09:58:51 GMT 2023 , Edited by admin on Sat Dec 16 09:58:51 GMT 2023
PRIMARY
Related Record Type Details
Structure of VALSARTAN
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966